Amgen Played Waiting Game Before Agreeing $3.7bn ChemoCentryx Deal

SEC Filings Show Tactical Negotiations

Amgen’s latest deal shows the biotech major’s need to replenish its portfolios and also the cool heads required when negotiations get heated.

Amgen
Amgen first opened talks with ChemoCentryx in early 2020, eventually paying $3.7bn for the company. • Source: Shutterstock

Amgen has a pressing need to replace revenues from major drugs facing loss of exclusivity, but the firm remained patient in its pursuit of ChemoCentryx, before agreeing a $3.7bn buyout.

More from Deals

More from Business